Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy: Metastatic Non-Small Cell Lung Cancer

Abstract

an AESI reported in 2% of pts in the N single-agent treatment to progression phase were rash (Any Gr: 25.5%; Gr 3: 4.0%, hypomagnesemia (Any Gr: 16.0%; Gr 3: 2.5%), conjunctivitis (Any Gr: 4.7%; Gr 3: 0.7%), venous thromboembolic events (Any Gr: 2.5%; Gr 3 1.8%), and arterial thromboembolic events (Any Gr: 2.2%; Gr 3: 1.8%). Conclusions: OS and PFS were statistically significantly improved when N was added to GC. Pts who continued on N single-agent to progression had substantially better outcomes than the general population, and long-term use of N did not result in any unexpected increases in AESIs. Author Disclosure: M.A. Socinski: None. N. Thatcher: F. Honoraria; Eli Lilly and others. H. Speakers Bureau; Eli Lilly and others. K. Advisory Board; Eli Lilly and others. A.V. Luft: None. A. Szczesna: None. T. Ciuleanu: None. W. Szafra nski: None. R. Ramlau: None. B. Balint: None. A. Kazarnowicz: None. O. Molinier: G. Consultant; Eli Lilly. K. Advisory Board; Roche. H. Depenbrock: A. Employee; Eli Lilly. M. Stock; Eli Lilly. S. Nanda: A. Employee; Eli Lilly. M. Stock; Eli Lilly. C. Obasaju: A. Employee; Eli Lilly. M. Stock; Eli Lilly. N. Stock Options; Eli Lilly. L. Paz-Ares: F. Honoraria; Eli Lilly.